What is the 13F Pro Quality Score for VNRX?

13F Pro ranks VOLITIONRX LTD (VNRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VNRX's current score at https://13fpro.ai/research/VNRX (free sign-up required for the full ranking).

Where does 13F Pro source VNRX data?

All VOLITIONRX LTD fundamentals and ownership data come directly from SEC EDGAR. VOLITIONRX LTD files with the SEC under CIK 93314. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VNRX in?

VOLITIONRX LTD (VNRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VNRX research updated on 13F Pro?

VNRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

VOLITIONRX LTD(VNRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 93314 VNRX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.7M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

VNRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for VOLITIONRX LTD (VNRX), a Healthcare sector company. VNRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), VOLITIONRX LTD reports quarterly revenue of $985.1K, net income of $-6.7M, free cash flow of $-5.3M. Top institutional holders of VNRX by reported 13-F value include Lagoda Investment Management, L.P., GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. VNRX trades on the NYSE exchange and files with the SEC under CIK 93314. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VNRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VOLITIONRX LTD directly from SEC EDGAR.

Revenue

Q1 2026

$985.1K

Net Income

Q1 2026

$-6.7M

Free Cash Flow

Q1 2026

$-5.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+122.8% YoY

$1.7MFY 2025

FY21 $90.0KFY22 $306.4KFY23 $775.3KFY25 $1.7M

Net Income

+34.5% YoY

$-23.4MFY 2025

FY21 $137.0MFY22 $-30.6MFY23 $-35.7MFY25 $-23.4M

Operating Income

+39.6% YoY

$-21.7MFY 2025

FY21 $-28.3MFY22 $-31.8MFY23 $-36.0MFY25 $-21.7M

EPS (Diluted)

—FY 2025

FY21 —FY22 —FY23 $-0.50FY25 —

Total Assets

-75.3% YoY

$6.9MFY 2025

FY21 $27.5MFY22 $18.3MFY23 $28.0MFY25 $6.9M

Total Debt

+25.8% YoY

$7.6MFY 2025

FY21 $3.9MFY22 $4.9MFY23 $6.0MFY25 $7.6M

Op. Cash Flow

-9.0% YoY

$-19.7MFY 2025

FY21 $-20.9MFY22 $-15.3MFY23 $-18.1MFY25 $-19.7M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018
Revenue	$1.7M +122.8%	$775.3K +153.0%	$306.4K +240.3%	$90.0K +426.6%	$17.1K	—
Net Income	$-23.4M +34.5%	$-35.7M -16.6%	$-30.6M -122.3%	$137.0M +252.6%	$-89.8M -398.7%	$-18.0M
Operating Income	$-21.7M +39.6%	$-36.0M -13.2%	$-31.8M -12.2%	$-28.3M -76.6%	$-16.0M +10.4%	$-17.9M
EPS (Diluted)	—	$-0.50	—	—	—	—
Total Assets	$6.9M -75.3%	$28.0M +52.8%	$18.3M -33.4%	$27.5M +29.1%	$21.3M +21.7%	$17.5M
Total Debt	$7.6M +25.8%	$6.0M +22.9%	$4.9M +27.1%	$3.9M +10.8%	$3.5M -9.3%	$3.8M
Operating Cash Flow	$-19.7M -9.0%	$-18.1M -18.2%	$-15.3M +26.7%	$-20.9M -63.7%	$-12.7M +13.5%	$-14.7M

AI Insight: VNRX Financial Trends

Pre-revenue biotech burning ~$5–7M quarterly with deteriorating equity position; minimal commercial progress despite two years of data.

• Revenue remains near-zero: $1M in Q3 2025 and Q1 2026, down from $0M throughout 2024.

• Operating losses stable at $5–6M per quarter; operating cash burn consistent at $4–7M quarterly.

• Equity eroded from -$22M (Q2 2024) to -$32M (Q1 2026), signaling cumulative losses outpacing any capital raises.

⚠ Equity swung to -$35M (Q4 2025), worst level on record; stabilized slightly at -$32M in Q1 2026.

⚠ Total debt drifted $6–8M range; leverage metrics deteriorate as equity becomes increasingly negative.

AI Insight: VNRX Ratio Trends

Insufficient financial data to assess VNRX trends — all key metrics absent across nine periods.

• No operating margin, net profit margin, return on equity, return on assets, return on invested capital, or debt-to-equity data available for any quarter Q2 2024–Q1 2026.

⚠ Complete absence of profitability and efficiency metrics prevents assessment of operational health or capital deployment quality.

Get alerted when VNRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for VOLITIONRX LTD including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VNRX

Lagoda Investment Management, L.P.
$3.3M16,149,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$248.5K1,230,083 sh
VANGUARD CAPITAL MANAGEMENT LLC
$204.8K1,013,673 sh
LUMINUS MANAGEMENT LLC
$201.0K995,000 sh
STATE STREET CORP
$137.3K679,938 sh
VANGUARD FIDUCIARY TRUST CO
$101.5K502,657 sh
BlackRock, Inc.
$90.1K446,187 sh
NORTHERN TRUST CORP
$52.4K259,593 sh
Silverberg Bernstein Capital Management LLC
$50.7K251,215 sh
Wealthspire Advisors, LLC
$44.4K220,000 sh

Fund	Value	Shares
Lagoda Investment Management, L.P.	$3.3M	16,149,000
GEODE CAPITAL MANAGEMENT, LLC	$248.5K	1,230,083
VANGUARD CAPITAL MANAGEMENT LLC	$204.8K	1,013,673
LUMINUS MANAGEMENT LLC	$201.0K	995,000
STATE STREET CORP	$137.3K	679,938
VANGUARD FIDUCIARY TRUST CO	$101.5K	502,657
BlackRock, Inc.	$90.1K	446,187
NORTHERN TRUST CORP	$52.4K	259,593
Silverberg Bernstein Capital Management LLC	$50.7K	251,215
Wealthspire Advisors, LLC	$44.4K	220,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VNRX on your watchlist

Track score changes the day VOLITIONRX LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VNRX a good stock to buy?

13F Pro's AI-powered analysis of VOLITIONRX LTD (VNRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VNRX are available on the VNRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VNRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VNRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VOLITIONRX LTD's investment landscape.